Investor Overview

Corporate Profile

Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within. Tocagen is currently studying its lead product candidate, Toca 511 & Toca FC, in a Phase 2/3 clinical trial for the treatment of patients with recurrent high grade glioma (HGG), a type of brain cancer with limited treatment options. Toca 511 & Toca FC has been granted Breakthrough Therapy Designation for the treatment of patients with recurrent HGG by the FDA.
NASDAQ GS TOCA (Common Stock)
$10.01 + 0.05
Stock chart for: TOCA.O.  Currently trading at $10.01 with a 52 week high of $17.95 and a 52 week low of $9.65.
10/18/17 10:31 a.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News

View All  

Tocagen to Present Updated Durable Response Data from Phase 1 Trial of Toca 511 & Toca FC in Recurrent Brain Cancer at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics


Read More

Tocagen Reports Second Quarter 2017 Financial and Business Results


Read More

Tocagen to Report Second Quarter 2017 Financial Results on Wednesday, August 9


Read More

Recent Presentation

View All  
Download Documentation Corporate Presentation – June 20, 2017

Upcoming Events

View All  
There are currently no events scheduled.